BACKGROUND: Mutants with targeted gene deletion ('knockout') or insertion (transgenic) of D1, D2, D3, D4 and D5 dopamine (DA) receptor subtypes are complemented by an increasing variety of double knockout and transgenic-'knockout' models, together with knockout of critical components of DA receptor signalling cascades such as G alpha(olf)[G gamma7], adenylyl cyclase type 5, PKA [RIIbeta] and DARPP-32. However, it is increasingly recognised that these molecular techniques have a number of inherent limitations. Furthermore, there are poorly understood methodological factors that contribute to inconsistent phenotypic findings between laboratories. OBJECTIVE: This review seeks to document the impact of DA receptor subtype and related transduction mutants on our understanding of the behavioural roles of these entities, primarily at the level of unconditioned psychomotor behaviour. METHODS: It includes ethologically based and orofacial movement studies in our own laboratories, since these are the only studies to systematically compare each of the D1, D2, D3, D4 and D5 receptor and DARPP-32 signal transduction 'knockouts'. DISCUSSION: There is a particular emphasis on identifying methodological factors that might influence phenotypic effects and account for inconsistencies. The findings are offered empirically to (1) specify the extent of phenotypic diversity among individual DA receptor subtypes and transduction components and (2) indicate relationships between D1, D2, D3, D4 and D5 receptor subtype proteins, associated G alpha(i)/G alpha(s)/G alpha(olf)[G gamma7]-adenylyl cyclase type 5-PKA [RIIbeta]-DARPP-32 signalling cascades and behaviour. The findings are also offered heuristically as a base for such phenotypic comparisons at additional levels of behaviour so that a yet more complete phenotypic profile might emerge.
BACKGROUND: Mutants with targeted gene deletion ('knockout') or insertion (transgenic) of D1, D2, D3, D4 and D5 dopamine (DA) receptor subtypes are complemented by an increasing variety of double knockout and transgenic-'knockout' models, together with knockout of critical components of DA receptor signalling cascades such as G alpha(olf)[G gamma7], adenylyl cyclase type 5, PKA [RIIbeta] and DARPP-32. However, it is increasingly recognised that these molecular techniques have a number of inherent limitations. Furthermore, there are poorly understood methodological factors that contribute to inconsistent phenotypic findings between laboratories. OBJECTIVE: This review seeks to document the impact of DA receptor subtype and related transduction mutants on our understanding of the behavioural roles of these entities, primarily at the level of unconditioned psychomotor behaviour. METHODS: It includes ethologically based and orofacial movement studies in our own laboratories, since these are the only studies to systematically compare each of the D1, D2, D3, D4 and D5 receptor and DARPP-32 signal transduction 'knockouts'. DISCUSSION: There is a particular emphasis on identifying methodological factors that might influence phenotypic effects and account for inconsistencies. The findings are offered empirically to (1) specify the extent of phenotypic diversity among individual DA receptor subtypes and transduction components and (2) indicate relationships between D1, D2, D3, D4 and D5 receptor subtype proteins, associated G alpha(i)/G alpha(s)/G alpha(olf)[G gamma7]-adenylyl cyclase type 5-PKA [RIIbeta]-DARPP-32 signalling cascades and behaviour. The findings are also offered heuristically as a base for such phenotypic comparisons at additional levels of behaviour so that a yet more complete phenotypic profile might emerge.
Authors: Anh Hai Tran; Ryoi Tamura; Teruko Uwano; Tsuneyuki Kobayashi; Motoya Katsuki; Gen Matsumoto; Taketoshi Ono Journal: Proc Natl Acad Sci U S A Date: 2002-06-25 Impact factor: 11.205
Authors: Rachel E Nally; Fergal N McNamara; Jeremiah J Clifford; A Kinsella; Orna Tighe; David T Croke; Allen A Fienberg; Paul Greengard; John L Waddington Journal: Neuropsychopharmacology Date: 2003-12 Impact factor: 7.853
Authors: Laurel M Pritchard; Aaron D Logue; Scott Hayes; Jeffrey A Welge; Ming Xu; Jianhua Zhang; S Paul Berger; Neil M Richtand Journal: Neuropsychopharmacology Date: 2003-01 Impact factor: 7.853
Authors: David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Gerard J O'Sullivan; Mark Dunleavy; Kerstin Hakansson; Mario Clementi; Anthony Kinsella; David T Croke; John Drago; Allen A Fienberg; Paul Greengard; David R Sibley; Gilberto Fisone; David C Henshall; John L Waddington Journal: Neuropharmacology Date: 2008-02-21 Impact factor: 5.250
Authors: Judith Mosinger Ogilvie; Angela M Hakenewerth; Rachel R Gardner; Joshua G Martak; Virginia M Maggio Journal: Mol Vis Date: 2009-12-23 Impact factor: 2.367